FASLODEXTM is indicated as monotherapy for the treatment of oestrogen receptor positive, locally advanced or metastatic breast cancer in postmenopausal women:
- Not previously treated with endocrine therapy, or
- With disease relapse on or after adjuvant antioestrogen therapy, or disease progression on antioestrogen therapy
Faslodex is also indicated in combination with palbociclib for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in women who have received prior endocrine therapy.
- In pre- or perimenopausal women, the combination treatment with palbociclib should be combined with a luteinising hormone releasing hormone agonist.
FASLODEX MONOTHERAPY AFTER PRIOR ENDOCRINE THERAPY
CONFIRM STUDY EFFICACY
CONFIRM STUDY PRIMARY ENDPOINT: PFS
FASLODEX 500 mg demonstrated efficacy as monotherapy in postmenopausal women with hormone receptor (HR)-positive ABC with disease progression following endocrine therapy2,4
Adapted from Di Leo A, et al. J Clin Oncol. 2010;28(30):4594-4600.2
CONFIRM final OS analysis at 75% maturity*6
Nominal p-value with no adjustments made for multiplicity between the initial overall survival analysis at 50% maturity and the updated survival analysis at 75% maturity.
Adapted from Di Leo A, et al. J Natl Cancer Inst. 2014;106(1):djt337
*No adjustments for multiplicity were made.